NASDAQ:GBIO Generation Bio (GBIO) Stock Price, News & Analysis $0.39 +0.02 (+4.73%) As of 01:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Generation Bio Stock (NASDAQ:GBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Generation Bio alerts:Sign Up Key Stats Today's Range$0.37▼$0.4050-Day Range$0.32▼$0.5852-Week Range$0.32▼$4.34Volume56,806 shsAverage Volume285,113 shsMarket Capitalization$26.27 millionP/E RatioN/ADividend YieldN/APrice Target$7.33Consensus RatingBuy Company OverviewGeneration Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More… Generation Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreGBIO MarketRank™: Generation Bio scored higher than 69% of companies evaluated by MarketBeat, and ranked 135th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGeneration Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGeneration Bio has only been the subject of 3 research reports in the past 90 days.Read more about Generation Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Generation Bio are expected to grow in the coming year, from ($1.75) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Generation Bio is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Generation Bio is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneration Bio has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Generation Bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.65% of the float of Generation Bio has been sold short.Short Interest Ratio / Days to CoverGeneration Bio has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Generation Bio has recently decreased by 1.18%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneration Bio does not currently pay a dividend.Dividend GrowthGeneration Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.65% of the float of Generation Bio has been sold short.Short Interest Ratio / Days to CoverGeneration Bio has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Generation Bio has recently decreased by 1.18%, indicating that investor sentiment is improving. News and Social MediaN/ANews SentimentN/A Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Generation Bio insiders have not sold or bought any company stock.Percentage Held by Insiders21.10% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.22% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Generation Bio's insider trading history. Receive GBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GBIO Stock News HeadlinesGeneration Bio to Present at the Needham 24th Annual Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comWedbush Keeps Their Buy Rating on Generation Bio (GBIO)March 18, 2025 | markets.businessinsider.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.May 7, 2025 | Paradigm Press (Ad)Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN) and Generation Bio (GBIO)March 17, 2025 | markets.businessinsider.comGeneration Bio Co. Advances in Autoimmune TherapeuticsMarch 15, 2025 | tipranks.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sutro Biopharma (STRO) and Generation Bio (GBIO)March 13, 2025 | markets.businessinsider.comGeneration Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsMarch 13, 2025 | globenewswire.comGeneration Bio to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comSee More Headlines GBIO Stock Analysis - Frequently Asked Questions How have GBIO shares performed this year? Generation Bio's stock was trading at $1.06 on January 1st, 2025. Since then, GBIO stock has decreased by 63.0% and is now trading at $0.3920. View the best growth stocks for 2025 here. How were Generation Bio's earnings last quarter? Generation Bio Co. (NASDAQ:GBIO) released its quarterly earnings results on Wednesday, March, 19th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.01. The business earned $4.19 million during the quarter, compared to analyst estimates of $2.92 million. Generation Bio had a negative net margin of 782.86% and a negative trailing twelve-month return on equity of 104.85%. When did Generation Bio IPO? Generation Bio (GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Generation Bio's major shareholders? Generation Bio's top institutional shareholders include EWA LLC (0.14%). Insiders that own company stock include Phillip Samayoa, Antoinette Paone and Dannielle Appelhans. View institutional ownership trends. How do I buy shares of Generation Bio? Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Generation Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Generation Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD). Company Calendar Last Earnings3/19/2025Today5/07/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GBIO CIK1733294 Webgenerationbio.com Phone617-655-7500FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$7.33 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,859.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,610,000.00 Net Margins-782.86% Pretax Margin-782.86% Return on Equity-104.85% Return on Assets-49.54% Debt Debt-to-Equity RatioN/A Current Ratio6.34 Quick Ratio6.34 Sales & Book Value Annual Sales$19.89 million Price / Sales1.26 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book0.12Miscellaneous Outstanding Shares67,013,000Free Float52,700,000Market Cap$25.08 million OptionableOptionable Beta2.76 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:GBIO) was last updated on 5/7/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generation Bio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Generation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.